Raras
Buscar doenças, sintomas, genes...
Leucoencefalopatia de início na idade adulta com esferoides axonais e glia pigmentada
ORPHA:313808CID-10 · G93.4OMIM 221820DOENÇA RARA

É uma doença genética rara, que a pessoa desenvolve ao herdar apenas uma cópia de um gene alterado de um dos pais. É caracterizada por um conjunto complexo de sintomas que pioram com o tempo, incluindo: perda progressiva das funções mentais (demência), dificuldade para fazer movimentos coordenados e com propósito (apraxia), falta de interesse ou motivação (apatia), problemas de equilíbrio, sintomas semelhantes aos da doença de Parkinson, rigidez muscular e espasmos involuntários, e convulsões.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É uma doença genética rara, que a pessoa desenvolve ao herdar apenas uma cópia de um gene alterado de um dos pais. É caracterizada por um conjunto complexo de sintomas que pioram com o tempo, incluindo: perda progressiva das funções mentais (demência), dificuldade para fazer movimentos coordenados e com propósito (apraxia), falta de interesse ou motivação (apatia), problemas de equilíbrio, sintomas semelhantes aos da doença de Parkinson, rigidez muscular e espasmos involuntários, e convulsões.

Pesquisas ativas
1 ensaio
6 total registrados no ClinicalTrials.gov
Publicações científicas
112 artigos
Último publicado: 2026 Mar 31

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Casos conhecidos
27
pacientes catalogados
Início
Adult
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: G93.4
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
11 sintomas
🫃
Digestivo
1 sintomas
👂
Ouvidos
1 sintomas

+ 22 sintomas em outras categorias

Características mais comuns

100%prev.
Disfagia
Frequência: 3/3
100%prev.
Distúrbio da marcha
Frequência: 3/3
100%prev.
Convulsão
Frequência: 3/3
100%prev.
Função executiva prejudicada
Frequência: 3/3
100%prev.
Parkinsonismo
Frequência: 3/3
100%prev.
Comprometimento da memória
Frequência: 3/3
35sintomas
Muito frequente (9)
Frequente (5)
Sem dados (21)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 35 características clínicas mais associadas, ordenadas por frequência.

DisfagiaDysphagia
Frequência: 3/3100%
Distúrbio da marchaGait disturbance
Frequência: 3/3100%
ConvulsãoSeizure
Frequência: 3/3100%
Função executiva prejudicadaImpaired executive functioning
Frequência: 3/3100%
ParkinsonismoParkinsonism
Frequência: 3/3100%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico112PubMed
Últimos 10 anos129publicações
Pico202427 papers
Linha do tempo
2026Hoje · 2026🧪 2014Primeiro ensaio clínico📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

2 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant.

AARS2Alanine--tRNA ligase, mitochondrialDisease-causing germline mutation(s) (loss of function) inTolerante
FUNÇÃO

Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala). Also edits incorrectly charged tRNA(Ala) via its editing domain (PubMed:21549344). In presence of high levels of lactate, also acts as a protein lactyltransferase that mediates lactylation of lysine residues in target proteins, such as CGAS (PubMed:39322678). Acts as an inhibitor of cGAS/STING signaling by catalyzing lac

LOCALIZAÇÃO

Mitochondrion

VIAS BIOLÓGICAS (1)
Mitochondrial tRNA aminoacylation
MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 8

A mitochondrial disease characterized by a lethal infantile hypertrophic cardiomyopathy, generalized muscle dysfunction and some neurologic involvement. The liver is not affected.

OUTRAS DOENÇAS (4)
leukoencephalopathy, progressive, with ovarian failurecombined oxidative phosphorylation defect type 8leukoencephalopathy, diffuse hereditary, with spheroids 1obsolete ovarioleukodystrophy
HGNC:21022UniProt:Q5JTZ9
CSF1RMacrophage colony-stimulating factor 1 receptorDisease-causing germline mutation(s) (loss of function) inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for CSF1 and IL34 and plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of pro-inflammatory chemokines in response to IL34 and CSF1, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
Other interleukin signalingTranscriptional Regulation by VENTXSignaling by CSF1 (M-CSF) in myeloid cells
EXPRESSÃO TECIDUAL(Ubíquo)
Baço
206.9 TPM
Nervo tibial
49.7 TPM
Tecido adiposo
38.0 TPM
Pulmão
37.9 TPM
Adipose Visceral Omentum
34.3 TPM
OUTRAS DOENÇAS (3)
leukoencephalopathy, diffuse hereditary, with spheroids 1brain abnormalities, neurodegeneration, and dysosteosclerosisearly-onset calcifying leukoencephalopathy-skeletal dysplasia
HGNC:2433UniProt:P07333

Variantes genéticas (ClinVar)

334 variantes patogênicas registradas no ClinVar.

🧬 CSF1R: NM_001288705.3(CSF1R):c.1937T>A (p.Ile646Asn) ()
🧬 CSF1R: NM_001288705.3(CSF1R):c.2213_2214dup (p.Glu739fs) ()
🧬 CSF1R: NM_001288705.3(CSF1R):c.2453C>A (p.Pro818His) ()
🧬 CSF1R: NM_001288705.3(CSF1R):c.551G>C (p.Arg184Thr) ()
🧬 CSF1R: NM_001288705.3(CSF1R):c.1778T>G (p.Phe593Cys) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Leucoencefalopatia de início na idade adulta com esferoides axonais e glia pigmentada

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
107 papers (10 anos)
#1

CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease.

Alzheimer's research &amp; therapy2026 Feb 07

Growing evidence supports that epigenetic dysregulation through histone deacetylases (HDACs) plays a critical role in synaptic dysfunction and memory loss in Alzheimer’s disease (AD), and that HDACs have been highlighted as an attractive class of targets for AD therapy. Moreover, restoring Wnt/β-catenin signaling, which is greatly suppressed in AD brains, is a promising therapeutic strategy. CI-994 is an orally active class I HDAC inhibitor that has undergone several phase II/III clinical trials on cancer treatment. Importantly, CI-994 can cross the blood–brain barrier and is a cognitive enhancer. Wnt activity was initially examined by Wnt reporter activity assay in Wnt3A-expression HEK293 cells, and profiling HDAC inhibition was performed against 10 individual HDACs. Activities of CI-994 on class I HDACs and Wnt/β-catenin signaling were further tested in HEK293 cells, LRP6-expressing HT1080 cells and neuronal SH-SY5Y cells. The therapeutic effects of CI-994 were examined in patient-specific iPSC-derived neurons and cerebral organoids carrying APOE ε4/ε4 genotype or MAPT p.P301L mutation. We herein report that CI-994 is not only a potent class I HDAC inhibitor but also an activator of Wnt/β-catenin signaling. Mechanistically, activation of Wnt/β-catenin signaling by CI-994 is associated with stabilizing Wnt co-receptor LRP6 protein and modulating HDAC activity. Importantly, CI-994 significantly increases histone acetylation, activates Wnt/β-catenin signaling, and decreases tau phosphorylation in patient-specific iPSC-derived cerebral organoids carrying APOE ε4/ε4 genotype or MAPT p.P301L mutation. Moreover, studies with the specific Wnt inhibitor LGK974 demonstrate that activation of Wnt/β-catenin signaling contributes to CI-994-induced the inhibition of tau phosphorylation in the iPSC-derived cerebral organoids. Additionally, CI-994 increases synaptic protein levels, enhances spontaneous synaptic firing and network formation and decreases tau phosphorylation in iPSC-derived neurons. Finally, RNA sequencing, combined with RT-qPCR validation, of the iPSC-derived cerebral organoids reveals that CI-994 significantly regulates genes associated with synapse plasticity and cognitive function including NEUROD1, CACNA1G, NRGN, NRTN, SLC7A10 and OMG. Our findings suggest that CI-994 can be repurposed as a novel therapeutic agent for AD therapy. The online version contains supplementary material available at 10.1186/s13195-026-01982-0.

#2

Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Associated with the CSF1R p. (Ile843Thr) Variant: Clinical, Imaging, and Molecular Characterization.

Internal medicine (Tokyo, Japan)2026 Feb 01

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a microgliopathy caused by pathogenic CSF1R variants. We report the first Japanese case of ALSP harboring the CSF1R p. (Ile843Thr) variant. The patient presented with progressive cognitive and behavioral decline followed by motor dysfunction, and MRI showed frontoparietal-predominant white matter lesions and corpus callosum thinning. A functional analysis demonstrated impaired autophosphorylation of the mutant protein, confirming pathogenicity. This case expands the CSF1R variants spectrum of ALSP and highlights the diagnostic value of integrating genetic testing with functional validation in adult-onset leukoencephalopathies, even when family history is absent.

#3

Targeted plasma proteomics uncover proteins associated with KIF5A-linked SPG10 and ALS spectrum disorders.

HGG advances2026 Jan 15

KIF5A (Kinesin family member 5A) is a motor protein that functions as a key component of the axonal transport machinery. Variants in KIF5A are linked to several neurodegenerative diseases, mainly spastic paraplegia type 10 (SPG10), Charcot-Marie-Tooth disease type 2 (CMT2), and amyotrophic lateral sclerosis (ALS). These diseases share motor neuron involvement but vary significantly in clinical presentation, severity, and progression. KIF5A variants are mainly categorized into N-terminal variants associated with SPG10/CMT2 and C-terminal variants linked to ALS. This study utilized a multiplex NULISA targeted platform to analyze plasma proteome from KIF5A-linked SPG10 and ALS individuals and compare them to healthy controls. Our results revealed distinct proteomic signatures, with significant alterations in proteins related to synaptic function and inflammation. Notably, neurofilament light polypeptide, a biomarker for neurodegenerative diseases, was elevated in KIF5A ALS but not in SPG10 individuals. Moreover, these findings can now be used to gain mechanistic understanding of axonopathies linking to N- versus C-terminal KIF5A variants affecting both central and peripheral nervous systems.

#4

Early subtypes and progressions of progressive supranuclear palsy: a data-driven brain bank study.

Journal of neurology2025 Oct 17

Progressive supranuclear palsy (PSP) is typically characterized by vertical supranuclear gaze palsy and early falls, referred to as Richardson's syndrome (PSP-RS). Other presentations include postural instability (PSP-PI), Parkinsonism (PSP-P), speech/language disorder (PSP-SL), frontal presentation (PSP-F), ocular motor dysfunction (PSP-OM), and corticobasal syndrome (PSP-CBS). However, differences across the early presentations and their subsequent clinical courses remain to be elucidated. This study aimed to characterize early PSP subtypes and their subsequent progressions using a large postmortem dataset. An automated pipeline incorporating fine-tuned Chat Generative Pretrained Transformer (ChatGPT) was developed. The pipeline collected 195 clinical features with onset information from autopsy-confirmed PSP cases without significant neurodegenerative co-pathologies. A structured clinicopathologic dataset from 588 patients was analyzed. The results from unsupervised clustering were distilled into a decision tree model. The mutually exclusive algorithm identified seven subtypes: PSP-PF (postural and frontal dysfunction), PSP-RS, PSP-PI, PSP-P, PSP-SL, PSP-F, and PSP-OM, based on five clinical manifestations: frontal presentation, postural instability, ocular motor dysfunction, speech/language disorder, and Parkinsonism. PSP-PF showed rapid progression, the shortest median disease duration (six years), and high tau burden in cortical and subcortical regions. In PSP-F, frontal presentation preceded other symptoms by four years, with a nine-year disease duration-second longest after PSP-P (10 years). PSP-CBS was not identified as an independent subtype. This data-driven study identified a novel, aggressive PSP phenotype characterized by early postural and frontal dysfunction. Early subtyping using the decision tree model would help clinicians estimate progression and facilitate early patient recruitment for clinical trials.

#5

Microglia replacement halts the progression of microgliopathy in mice and humans.

Science (New York, N.Y.)2025 Jul 10

Colony-stimulating factor 1 receptor (CSF1R) is primarily expressed in microglia. Its monoallelic mutation causes CSF1R-associated microgliopathy (CAMP), a major form of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and a fatal neurological disease without clinical cure. We developed mouse models harboring human hotspot mutations of CAMP and replaced CSF1R-deficient microglia with CSF1R-normal cells through microglia replacement by bone marrow transplantation (Mr BMT), which attenuated pathology in mice. We further demonstrated that, in the context of CSF1R deficiency, traditional bone marrow transplantation (tBMT) in ALSP functions similarly to Mr BMT, efficiently replacing microglia and reducing disease progression. We then replaced CSF1R-deficient microglia in eight patients by tBMT. The disease progression was halted during the 24-month follow-up. Together, microglia replacement corrects pathogenic mutations and halts disease progression in mice and humans.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC56 artigos no totalmostrando 126

2026

CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease.

Alzheimer's research &amp; therapy
2026

Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Associated with the CSF1R p. (Ile843Thr) Variant: Clinical, Imaging, and Molecular Characterization.

Internal medicine (Tokyo, Japan)
2025

Early subtypes and progressions of progressive supranuclear palsy: a data-driven brain bank study.

Journal of neurology
2025

A Novel Radiographic and Genetic Variant of Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Case Report.

The Neurohospitalist
2025

Rare FN1 missense mutations indicate a protective role against Lewy body dementia in APOEε4 homozygous carriers.

Acta neuropathologica
2026

Targeted plasma proteomics uncover proteins associated with KIF5A-linked SPG10 and ALS spectrum disorders.

HGG advances
2025

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia mimicking adult-onset Krabbe disease.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2025

Hematopoietic Stem Cell Transplantation in an International Cohort of Colony Stimulating Factor-1 Receptor (CSF1R)-Related Disorder.

Movement disorders : official journal of the Movement Disorder Society
2025

Microglia replacement halts the progression of microgliopathy in mice and humans.

Science (New York, N.Y.)
2025

Mutations in the human CSF1R gene impact microglia's maintenance of brain white matter integrity.

Nature immunology
2025

Evaluating Glial Fibrillary Acidic Protein and Neurofilament Light as Potential Biomarkers for Spinocerebellar Ataxia 7.

International journal of molecular sciences
2025

Colony-stimulating factor-1 receptor-related disorder in the Hispanic population.

Parkinsonism &amp; related disorders
2025

Genetic diseases misdiagnosed as multiple sclerosis: Observational study and review of literature.

Multiple sclerosis and related disorders
2025

KIF5A variant in familial dystonia: A clinicogenetic study of a large Roma kindred.

Parkinsonism &amp; related disorders
2025

Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing.

Nature communications
2025

Microglia specific Csf1r haploinsufficiency induces depressive-like behaviors by promoting NLRP6/caspase-1 signaling in mice.

Brain, behavior, and immunity
2025

Phase 1, First-In-Human, Single-/Multiple-Ascending Dose Study of Iluzanebart in Healthy Volunteers.

Annals of clinical and translational neurology
2025

Expanding the Tyrosine Kinase Domain of CSF1R? A Case Report From an Adult-Onset Leukoencephalopathy.

American journal of medical genetics. Part A
2025

Author Correction: Clinical spectrum of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia in individuals of Korean ancestry.

Scientific reports
2025

Development and validation of a sensitive sandwich ELISA against human PINK1.

Autophagy
2025

Rescue of in vitro models of CSF1R-related adult-onset leukodystrophy by iluzanebart: mechanisms and therapeutic implications of TREM2 agonism.

Journal of neuroinflammation
2025

Clinical spectrum of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia in individuals of Korean ancestry.

Scientific reports
2025

Progressive dementia and seizures as distinguishing features in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Epileptic disorders : international epilepsy journal with videotape
2024

The effect of a dominant kinase-dead Csf1r mutation associated with adult-onset leukoencephalopathy on brain development and neuropathology.

Neurobiology of disease
2024

Mapping the journey of patients and care partners living with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: developing a framework for improvements in care.

Neurodegenerative disease management
2024

Structural and Functional Characterization of the Most Frequent Pathogenic PRKN Substitution p.R275W.

Cells
2024

Hematopoietic stem cell transplantation in leukodystrophies.

Handbook of clinical neurology
2024

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Handbook of clinical neurology
2024

Global Presence and Penetrance of CSF1R-Related Disorder.

Neurology. Genetics
2024

Deciphering glial contributions to CSF1R-related disorder via single-nuclear transcriptomic profiling: a case study.

Acta neuropathologica communications
2024

Heterozygous missense CSF1R variants hamper in vitro CD34+-derived dendritic cell generation but not in vivo dendritic cell development.

Molecular immunology
2024

Associations of mitochondrial genomic variation with successful neurological aging.

Mitochondrion
2024

Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.

Movement disorders : official journal of the Movement Disorder Society
2024

Specific Biomarkers in Spinocerebellar Ataxia Type 3: A Systematic Review of Their Potential Uses in Disease Staging and Treatment Assessment.

International journal of molecular sciences
2024

Novel variants in CSF1R associated with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

Journal of neurology
2024

Therapeutic potential of human microglia transplantation in a chimeric model of CSF1R-related leukoencephalopathy.

Neuron
2024

Systematic rare variant analyses identify RAB32 as a susceptibility gene for familial Parkinson's disease.

Nature genetics
2024

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP): Estimation of pathological lesion stage from brain images.

Journal of the neurological sciences
2024

Assessing Chitinases and Neurofilament Light Chain as Biomarkers for Adult-Onset Leukodystrophies.

Current issues in molecular biology
2024

Genome sequence analyses identify novel risk loci for multiple system atrophy.

Neuron
2024

An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders.

Molecular neurodegeneration
2024

Clinical presentation and diagnosis of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: a literature analysis of case studies.

Frontiers in neurology
2024

Up Close and Personal with Adult-Onset Leukoencephalopathy.

Journal of Alzheimer's disease : JAD
2024

miRNA family miR-29 inhibits PINK1-PRKN dependent mitophagy via ATG9A.

bioRxiv : the preprint server for biology
2024

Neuroimaging of CSF1R-related Disorder.

Radiology
2024

TMEM106B core deposition associates with TDP-43 pathology and is increased in risk SNP carriers for frontotemporal dementia.

Science translational medicine
2024

Novel Neuroimaging Pattern in POLR3A-Related Disorder on 7T MRI.

Neurology. Genetics
2024

Neurite-based white matter alterations in MAPT mutation carriers: A multi-shell diffusion MRI study in the ALLFTD consortium.

Neurobiology of aging
2024

CSF1R-related disorder: State of the art, challenges, and proposition of a new terminology.

Parkinsonism &amp; related disorders
2023

Validation Study of the MDS Criteria for the Diagnosis of Multiple System Atrophy in the Mayo Clinic Brain Bank.

Neurology
2023

Case 317: Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia.

Radiology
2023

Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PINK1-deficient Human Dopamine Neurons.

bioRxiv : the preprint server for biology
2023

Minocycline protects against microgliopathy in a Csf1r haplo-insufficient mouse model of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

Journal of neuroinflammation
2023

Adult-Onset Leukoencephalopathy with Axonal Spheroid and Pigmented Glia: Different Histological Spectrums Presented in Autopsy Cases of Siblings and a Surgical Case of Stereotactic Biopsy.

Diagnostics (Basel, Switzerland)
2023

Generation of a heterozygous and a homozygous CSF1R knockout line from iPSC using CRISPR/Cas9.

Stem cell research
2023

Report of A Family with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Without Mutations in CSF1R, AARS1 or AARS2.

Movement disorders clinical practice
2023

A case of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia presenting with alien hand syndrome.

eNeurologicalSci
2022

A Unique Radiological Correlate of CSF1R Mutation: "Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia - Sine Leukoencephalopathy".

Annals of Indian Academy of Neurology
2022

Hematopoietic Stem Cell Transplantation in CSF1R-Related Leukoencephalopathy: Retrospective Study on Predictors of Outcomes.

Pharmaceutics
2022

Chitotriosidase is a biomarker for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Annals of clinical and translational neurology
2022

Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Masquerading Primary Progressive Aphasia.

Annals of Indian Academy of Neurology
2022

Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) in an Indian Man.

Annals of Indian Academy of Neurology
2022

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia by a novel mutation of the CSF1R gene.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2022

A novel CSF1R variant in a South Dakota family with CSF1R-related leukoencephalopathy.

Parkinsonism &amp; related disorders
2022

Dominant-acting CSF1R variants cause microglial depletion and altered astrocytic phenotype in zebrafish and adult-onset leukodystrophy.

Acta neuropathologica
2022

The Primary Microglial Leukodystrophies: A Review.

International journal of molecular sciences
2022

A Rare Genetic Cause of Young Onset Rapidly Progressive Dementia- First Report from India.

Neurology India
2022

A kinase-dead Csf1r mutation associated with adult-onset leukoencephalopathy has a dominant inhibitory impact on CSF1R signalling.

Development (Cambridge, England)
2021

Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development.

Frontiers in neurology
2022

Handwriting impairment in a case of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia caused by a novel mutation in the CSF1R gene.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2021

Novel CSF1R variant in adult-onset leukoencephalopathy masquerading as frontotemporal dementia: a follow-up study.

Neurocase
2021

Recent Advances in Basic Research for CSF1R-Microglial Encephalopathy.

Frontiers in aging neuroscience
2021

Decreased CSF1R Signaling and the Accumulation of Reticular Pseudo-Drusen?

Ophthalmic surgery, lasers &amp; imaging retina
2022

Neuroimaging phenotypes of CSF1R-related leukoencephalopathy: Systematic review, meta-analysis, and imaging recommendations.

Journal of internal medicine
2021

Insights Into the Role of CSF1R in the Central Nervous System and Neurological Disorders.

Frontiers in aging neuroscience
2022

Teaching case 1-2020 - ADDENDUM: Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia due to a novel CSF1R mutation - An unusual cause of dementia.

Clinical neuropathology
2021

A case of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) with a high antinuclear antibody titer.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2022

Evaluation of CSF1R-related adult onset leukoencephalopathy with axonal spheroids and pigmented glia diagnostic criteria.

European journal of neurology
2021

Microglial dyshomeostasis drives perineuronal net and synaptic loss in a CSF1R+/- mouse model of ALSP, which can be rescued via CSF1R inhibitors.

Science advances
2021

Three novel mutations in Chinese patients with CSF1R-related leukoencephalopathy.

Annals of translational medicine
2021

Case report: 'AARS2 leukodystrophy'.

Molecular genetics and metabolism reports
2021

[Loss of homeostatic microglia in rare neurological disorders: implications for cell transplantation].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica
2021

Diffusion-Weighted Imaging is Key to Diagnosing Specific Diseases.

Magnetic resonance imaging clinics of North America
2021

Variants Affecting the C-Terminal of CSF1R Cause Congenital Vertebral Malformation Through a Gain-of-Function Mechanism.

Frontiers in cell and developmental biology
2021

Proteolytic Shedding of Human Colony-Stimulating Factor 1 Receptor and its implication.

Journal of cellular and molecular medicine
2021

Pathologic basis of the preferential thinning of thecorpus callosum in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

eNeurologicalSci
2021

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with an A792D mutation in the CSF1R gene in a Polish patient.

Neurologia i neurochirurgia polska
2020

Microglial replacement therapy: a potential therapeutic strategy for incurable CSF1R-related leukoencephalopathy.

Acta neuropathologica communications
2021

Microglial reduction of colony stimulating factor-1 receptor expression is sufficient to confer adult onset leukodystrophy.

Glia
2021

Distinctive diffusion-weighted imaging features in late-onset genetic leukoencephalopathies.

Neuroradiology
2020

Spinal Cord Involvement in Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia.

JAMA neurology
2020

Altered features of monocytes in adult onset leukoencephalopathy with axonal spheroids and pigmented glia: A clue to the pathomechanism of microglial dyshomeostasis.

Neurobiology of disease
2020

Microglial Homeostasis Requires Balanced CSF-1/CSF-2 Receptor Signaling.

Cell reports
2020

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia - An unusual cause of dementia.

Clinical neuropathology
2020

Biopsy histopathology in the diagnosis of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2019

A novel dominant-negative mutation of the CSF1R gene causes adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

American journal of translational research
2020

Factors predictive of the presence of a CSF1R mutation in patients with leukoencephalopathy.

European journal of neurology
2019

Haematopoietic stem cell transplantation in CSF1R-related adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Journal of neurology, neurosurgery, and psychiatry
2019

Homozygous Mutations in CSF1R Cause a Pediatric-Onset Leukoencephalopathy and Can Result in Congenital Absence of Microglia.

American journal of human genetics
2019

An Autopsy Proven Case of CSF1R-mutant Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) with Premature Ovarian Failure.

Experimental neurobiology
2019

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: A case report.

Radiology case reports
2019

[Retraction: Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: A case presented brain calcification and corpus callosum atrophy from over 10 years before the onset of dementia].

Rinsho shinkeigaku = Clinical neurology
2019

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: Clinical and imaging characteristics.

The neuroradiology journal
2018

AARS2 Compound Heterozygous Variants in a Case of Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia.

Journal of neuropathology and experimental neurology
2018

Early-onset dementia, leukoencephalopathy and brain calcifications: a clinical, imaging and pathological comparison of ALSP and PLOSL/Nasu Hakola disease.

Acta neurologica Belgica
2018

NfL is a biomarker for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Neurology
2018

Identification and functional characterization of novel mutations including frameshift mutation in exon 4 of CSF1R in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Journal of neurology
2018

Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia: An MRI Study of 16 French Cases.

AJNR. American journal of neuroradiology
2018

Colony-Stimulating Factor 1 Receptor (CSF1R) Regulates Microglia Density and Distribution, but Not Microglia Differentiation In Vivo.

Cell reports
2018

Generation of an induced pluripotent stem cell line from a patient with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP): HIHCNi003-A.

Stem cell research
2018

AARS2-related ovarioleukodystrophy: Clinical and neuroimaging features of three new cases.

Acta neurologica Scandinavica
2018

Partial loss of function of colony-stimulating factor 1 receptor in a patient with white matter abnormalities.

European journal of neurology
2018

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP): Integrating the literature on hereditary diffuse leukoencephalopathy with spheroids (HDLS) and pigmentary orthochromatic leukodystrophy (POLD).

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
2017

Pathologic Correlation of Paramagnetic White Matter Lesions in Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia.

Journal of neuropathology and experimental neurology
2018

Diagnostic criteria for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia due to CSF1R mutation.

European journal of neurology
2017

[Retraction:Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: A case presented brain calcification and corpus callosum atrophy from over 10 years before the onset of dementia].

Rinsho shinkeigaku = Clinical neurology
2018

Cognitive dysfunction and symptoms of movement disorders in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Parkinsonism &amp; related disorders
2017

Redefining the phenotype of ALSP and AARS2 mutation-related leukodystrophy.

Neurology. Genetics
2016

Analysis of Mutations in AARS2 in a Series of CSF1R-Negative Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia.

JAMA neurology
2017

Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with CSF1R mutation.

European journal of neurology
2017

Diagnostic Value of Brain Calcifications in Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia.

AJNR. American journal of neuroradiology
2017

Adult onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and Nasu-Hakola disease: lesion staging and dynamic changes of axons and microglial subsets.

Brain pathology (Zurich, Switzerland)
2016

A young-onset frontal dementia with dramatic calcifications due to a novel CSF1R mutation.

Neurocase
2016

Emerging Roles for CSF-1 Receptor and its Ligands in the Nervous System.

Trends in neurosciences
2015

Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia Caused by a Novel R782G Mutation in CSF1R.

Scientific reports
2015

Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia linked CSF1R mutation: Report of four Korean cases.

Journal of the neurological sciences

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Leucoencefalopatia de início na idade adulta com esferoides axonais e glia pigmentada.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Leucoencefalopatia de início na idade adulta com esferoides axonais e glia pigmentada

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. CI-994 is a dual modulator of class I HDACs and Wnt/&#x3b2;-catenin signaling for the treatment of Alzheimer's disease.
    Alzheimer's research &amp; therapy· 2026· PMID 41654970mais citado
  2. Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Associated with the CSF1R p. (Ile843Thr) Variant: Clinical, Imaging, and Molecular Characterization.
    Internal medicine (Tokyo, Japan)· 2026· PMID 41621886mais citado
  3. Targeted plasma proteomics uncover proteins associated with KIF5A-linked SPG10 and ALS spectrum disorders.
    HGG advances· 2026· PMID 40873038mais citado
  4. Early subtypes and progressions of progressive supranuclear palsy: a data-driven brain bank study.
    Journal of neurology· 2025· PMID 41107539mais citado
  5. Microglia replacement halts the progression of microgliopathy in mice and humans.
    Science (New York, N.Y.)· 2025· PMID 40638739mais citado
  6. Natural History of Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP): A Retrospective Patient Cohort Study.
    Neurol Ther· 2026· PMID 41915097recente
  7. Dissecting microglial contributions to neurodegenerative disease pathophysiology using human pluripotent stem cells.
    Stem Cell Reports· 2026· PMID 41895273recente
  8. A Novel Radiographic and Genetic Variant of Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Case Report.
    Neurohospitalist· 2025· PMID 40936738recente
  9. Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia mimicking adult-onset Krabbe disease.
    J Clin Neurosci· 2025· PMID 40768941recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:313808(Orphanet)
  2. OMIM OMIM:221820(OMIM)
  3. MONDO:0800027(MONDO)
  4. GARD:10981(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q63860020(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Leucoencefalopatia de início na idade adulta com esferoides axonais e glia pigmentada

ORPHA:313808 · MONDO:0800027
Prevalência
<1 / 1 000 000
Casos
27 casos conhecidos
Herança
Autosomal dominant
CID-10
G93.4 · Encefalopatia não especificada
Ensaios
1 ativos
Início
Adult
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C1857300
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades